Navigation Links
Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
Date:1/5/2012

DEERFIELD, Ill., Jan. 5, 2012 /PRNewswire/ -- Baxter International Inc. today announced the dosing of the first patients in a Phase I clinical trial of its lead investigational candidate, BAX 855, a longer-acting (PEGylated) form of a full-length recombinant factor VIII (rFVIII) protein.  BAX 855 is based on Baxter's ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method] full-length rFVIII molecule and plasma/albumin-free (PAF) manufacturing process.

The Phase I trial is a prospective, open-label study that will assess the safety, tolerability and pharmacokinetics of BAX 855 in previously-treated patients aged 12 years or older with severe hemophilia A.  When used for prophylaxis, Baxter's ADVATE requires patients to infuse every two to three days to reduce the occurrence of bleeding episodes.  This Phase I trial is the first step in assessing whether BAX 855 can be infused less frequently. 

"This trial is designed to provide new insights about our investigational longer-acting FVIII molecule, BAX 855, with the ultimate goal of improving care for patients living with hemophilia A," said Prof. Hartmut J. Ehrlich, M.D., vice president of global research and development in Baxter's BioScience business. "The Phase I results will serve as the foundation for advancing this important program through clinical development and determining whether BAX 855 can offer a treatment regimen requiring fewer infusions than ADVATE."

BAX 855 employs Baxter's proprietary full-length plasma/albumin-free recombinant protein platform that does not contain any human or animal-derived additives. BAX 855 leverages Nektar Therapeutics' (NASDAQ: NKTR) proprietary PEGylation technology, which is designed to extend the duration of activity of proteins and larger molecules.  Baxter and Nektar have a collaboration to develop PEGylated products designed
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Hikma Expands its Global Injectables Business Through the Acquisition of Baxter Healthcare Corporations Multi-Source Injectables Business
2. Variation Biotechnologies Names Jeff Baxter CEO
3. Baxter International First Quarter 2009 Financial Results Conference Call
4. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
5. Halozyme Receives $5.5 Million Payment From Baxter
6. Frost & Sullivan Awards Baxters BioPharma Solutions Business the 2008 North American Customer Service Leadership of the Year Award
7. AmeriCares Presents Power of Partnership Award to Baxter
8. Baxter International Third Quarter 2008 Financial Results Conference Call
9. Baxter Named to Dow Jones Sustainability Index for Tenth Consecutive Year
10. Baxter Announces Licensing Agreement for Innocolls Gentamicin Surgical Implant in the United States
11. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... TORONTO, May 5, 2015 /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: ... financial results for the three months ended March 31, ... all amounts are in Canadian dollars. ... year end from May 31 to December 31. As ... being reported is for the three months ended March ...
(Date:5/5/2015)... Mich. (PRWEB) May 05, 2015 ... publishing services to develop custom course materials for smaller ... annual enrollments as low as 200 students. , ... a broader range of higher education instructors,” said Jeff ... the country, we can do our part to make ...
(Date:5/5/2015)... IN (PRWEB) May 05, 2015 The ... the state of Indiana, led by Indiana Gov. Mike ... Day. The AMA Foundation will host a Family Fest ... celebration. All proceeds will benefit the Wounded Warrior Project. ... the Academy of Model Aeronautics—the country’s foremost organization for ...
(Date:5/5/2015)... , May 5, 2015  A group of biotechnology ... the Coma Research Institute, a non-profit organization dedicated to ... families suffering from disorders of consciousness.  ... http://photos.prnewswire.com/prnh/20150504/213779LOGO   ... consciousness, in which no voluntary actions can be initiated ...
Breaking Biology Technology:Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 2Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 3Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 4Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 5Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 6Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 7Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 8Hayden-McNeil Expands Publishing Program to Service Lower Enrollment Courses 2State of Indiana proclaims August 15 as Model Aviation Day 2Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 2Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 3Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 4Biotechnology Executives and Medical Doctors Team Up to Tackle Coma and Disorders of Consciousness 5
... 6, 2011 Biodel Inc. (Nasdaq: BIOD ... and CEO of Biodel, will present a corporate update ... January 13, 2011 at 9:30 a.m. Pacific Time (12:30 ... the development of new follow-on formulations of its lead ...
... Inc. (Nasdaq: ANDS ) today announced the following ... Directors: Kevin L. Eastwood has joined Anadys ... has been promoted to Senior Vice President, Research and Chief ... President, Drug Development and Chief Medical Officer, has been appointed ...
... LLC announces the release of their newest market report: ... Life Science Suppliers (#10-005) This report is for life ... fashion to the rapidly changing market for genomic analysis ... the market for genetic analysis including those products used ...
Cached Biology Technology:Anadys Pharmaceuticals Augments Management Team and Board of Directors 2Anadys Pharmaceuticals Augments Management Team and Board of Directors 3Anadys Pharmaceuticals Augments Management Team and Board of Directors 4BioInformatics, LLC New Market Report - Genomics Technologies 2
(Date:4/21/2015)... 21, 2015 High crime ... are boosting access control systems market in ... a recently published report by TechSci Research " Saudi ... access control systems market in Saudi Arabia ... 2020.The access control systems market in the Kingdom is ...
(Date:4/14/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces that its Wocket® smart ... Design Awards under the category  ,Product Design – Technology,. ... are part of a global multi-disciplinary awards program. The ... marketplace, industry and judging panel. Winners will be announced ...
(Date:4/8/2015)...  Infinisource, a leading provider of SaaS-based Human Capital ... leading supplier of biometric identification and security solutions, ... advanced biometrically-enabled time clock, the companies announced today. ... setting a bold, new standard for the collection ... and mid-size employer. When connected to the iSolved ...
Breaking Biology News(10 mins):Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... Arlington, VA (November 30, 2007) The CONRAD Program of ... received a $28.5 million grant from the Bill & Melinda ... date, the Gates Foundation has awarded a total of $65 ... award will support the development of new combination microbicides, research ...
... become increasingly homogenized as a result of climate change, ... Helmholtz Centre for Environmental Research writing in the international ... the composition and species numbers of plants on the ... the Bernina range in Switzerland over a period of ...
... advertising for commercial genetic testing is on the rise ... Hospital (MGH) physician. In the December issue of ... such testing is poorly regulated and may present potential ... tests that are being offered have no proven clinical ...
Cached Biology News:CONRAD receives $28.5M Gates Foundation grant for HIV prevention research 2Mountain summits in the Alps becoming increasingly similar 2Direct-to-consumer advertising for genetic tests concerns physicians and may mislead patients 2
... The CopyControl™ vector can be induced prior ... vectors provide the stability of single-copy BACs ... or other cloning vectors. The kits provide ... reagents, insert size screening system) necessary to ...
...
... cells were cultured in DMEM with 4 mM ... growth. In order to keep the antigens ... acetone-methanol. The cells are arrayed on a ... wells surface specifically treated to enhance cellular attachment ...
... HistoMark Biotin Streptavidin-HRP Systems provide rapid, ... intracellular antigens in frozen or paraffin-embedded ... These systems also facilitate double or ... be performed simultaneously with primary antibodies ...
Biology Products: